Ben Sasse on the Senate's "smack-down nonsense" and his wish for America

Former Sen. Ben Sasse used a CBS interview and town hall to argue Congress is too focused on partisan theatrics and should prioritize long-term issues, especially AI-driven economic disruption and institutional change. He also highlighted his stage-four pancreatic cancer treatment with daraxonrasib, saying it has reduced tumor volume by 76% over four months and renewed his call to broaden access to experimental therapies under right-to-try rules. The piece is primarily a political and policy commentary with limited direct market impact.

Analysis

The market implication is not the political commentary itself, but the policy aperture it widens around decentralized access to experimental oncology. If Washington’s mood shifts toward “patient autonomy over regulator gatekeeping,” the first-order beneficiaries are not just single-asset biotech names, but the broader late-stage development stack: CROs, trial-enablement tools, and specialty distributors that profit from more protocol-heavy experimentation. For RVMDW specifically, the read-through is asymmetric because any expansion in “right to try” norms or faster off-label adoption can pull forward commercial mindshare well before a clean FDA-label story is complete.

The second-order risk is that the same narrative also raises scrutiny. A more permissive access regime can invite headline-driven pushback after adverse events, creating discontinuous sentiment shocks for names associated with terminal-disease therapies. That makes the next 1-3 quarters less about valuation expansion and more about execution durability: manufacturing consistency, compassionate-use data, and whether prescribers treat the signal as a real survival delta rather than an anecdote. In other words, RVMDW has a path to multiple re-rating, but also a non-trivial risk of air-pocket drawdowns if the public debate turns to safety or equity concerns.

On the AI side, the article reinforces a longer-dated labor-disruption regime, but the investable angle is to separate beneficiaries of automation from the politically exposed casualties. Over 12-36 months, software and infrastructure tied to model deployment should remain supported, while sectors with routinized workflows face margin pressure from substitution and wage compression. The contrarian view is that the consensus is probably overestimating the speed of labor displacement and underestimating institutional friction; that favors owning picks-and-shovels more than direct “AI winner” narratives.

Key Decisions for Investors

• Long RVMDW on weakness for a 3-6 month trade; use a 15-20% trailing stop. Upside comes from optionality around broader access narratives and clinical momentum, but expect headline volatility.
• Pair trade: long RVMDW / short a basket of lower-quality pre-revenue oncology names over the next 1-2 quarters. The market is likely to reward assets with visible survival benefit and punish story-only biotech if capital gets more selective.
• Add exposure to healthcare trial-enablement beneficiaries (e.g., ICLR, IQV) on a 6-12 month horizon. More experimentation and decentralized access should support protocol volumes and data-management demand with lower single-drug risk.
• Maintain or add AI infrastructure exposure via semis/data-center supply chain rather than application-layer software for a 12-24 month horizon. The policy debate here supports continued capex, while labor disruption remains slower than headline narratives imply.
• Use downside hedges on highly automated service/clerical-heavy sectors over 6-18 months. The macro risk is not immediate job loss, but eventual margin compression as firms adopt AI to reduce routine labor costs.